<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818492</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0501-04</org_study_id>
    <secondary_id>2012-003632-23</secondary_id>
    <nct_id>NCT01818492</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis</brief_title>
  <official_title>A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovImmune SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seventh Framework Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NovImmune SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and efficacy of a new drug
      aimed at controlling disease activity in patients diagnosed with primary haemophagocytic
      lymphohistiocytosis. The new drug can be administered as the first-line therapy, to patients
      not previously treated with the current standard of care, or can be given to patients who
      have either failed or were unable to tolerate the current standard of care. Administration
      will be on top of a glucocorticosteroid, which is usually part of the current recommended
      treatment.

      All participants in the NI-0501-04 study (NCT01818492) were invited to participate in the
      long-term follow-up study NI-0501-05 (NCT02069899). For the primary completion date,
      mentioned here, we refer to the NI-0501-04 study, even though in accordance with the
      NI-0501-04 study objectives, namely the assessment of long-term efficacy and safety
      endpoints, the study analyses also included data collected in the long-term follow-up study
      NI-0501-05. Hence these data are reported together. Study NI-0501-05 is ongoing, and data
      from this study are reported as available at 31 January 2019.

      The primary efficacy and safety analyses are based on the regulatory cut-off date of 20 July
      2017. Refer to the publication in N Engl J Med 2020 May 7; 382 (19):1811-1822. Follow-on
      analyses have been conducted on all patients enrolled in the study, i.e. including the
      patients enrolled after the cut-off date of 20 July 2017. The results reported here refer to
      the totality of the 45 patients enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>any time during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of response</measure>
    <time_frame>any time during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>end of the study and beyond</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucocorticoid tapering</measure>
    <time_frame>any time during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of NI-0501 in haemophagocytic lymphohistiocytosis</measure>
    <time_frame>up to end of the study</time_frame>
    <description>Vital signs
Physical examination
Recording of adverse events
Routine laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of response</measure>
    <time_frame>up to start of HSCT conditioning, whenever HSCT conditioning is scheduled (at least 4 weeks after treatment start)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Primary Haemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>NI-0501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NI-0501</intervention_name>
    <arm_group_label>NI-0501</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: male and female

          -  Age: up to and including 18 years at diagnosis of Haemophagocytic Lymphohistiocytosis

          -  Primary HLH patients

          -  Patient (if ≥ 18 years old), or patient's legal representative(s) must have signed
             informed consent

        Exclusion Criteria:

          -  Diagnosis of secondary Haemophagocytic Lymphohistiocytosis consequent to a proven
             rheumatic or neoplastic disease.

          -  Body weight &lt; 3 kg.

          -  Patients treated with biologics within a specific timeframe

          -  Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter and
             Leishmania infections.

          -  Presence of malignancy.

          -  Concomitant disease or malformation severely affecting the cardiovascular, pulmonary,
             liver or renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-7106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital - Division of Immunobiology - Department of Pediatrics</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Meyer</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Padova - Clinica di Oncoematologia Pediatrica</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu'</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Donna Bambino - U.O.C. Oncoematologia Pediatrica</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>119-129</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital - Department of Haematology</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Turkey</country>
  </removed_countries>
  <link>
    <url>https://www.clinicaltrials.gov/ct2/show/NCT02069899</url>
    <description>NI-0501-05, long-term follow-up study description on clinicaltrials.gov</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Emapalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: US protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 24, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT01818492/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: EU protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 26, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT01818492/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT01818492/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>June 26, 2020</submitted>
    <returned>July 24, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

